Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 3/2014

01-03-2014 | Clinical Practice: Clinical Vignettes

Use of a Once-Daily NSAID in Treatment of Cyclic Vomiting Syndrome

Authors: Mahesh K. Vidula, BS, Anil Wadhwani, BA, Kaleigh Roberts, BS, Lyle L. Berkowitz, MD, FACP

Published in: Journal of General Internal Medicine | Issue 3/2014

Login to get access

ABSTRACT

Cyclic vomiting syndrome (CVS) is a rare disorder characterized by episodes of intense vomiting and nausea separated by symptom-free periods. We report the case of a 71-year-old man who presented with a long history of poorly controlled CVS whose symptoms resolved with the addition of a once-daily dose of meloxicam, a semi-selective non-steroidal anti-inflammatory drug (NSAID). This is the first report of symptom alleviation in a CVS patient using a once-daily NSAID, as well as one with selectivity to COX-2 inhibition. This is important due to both the increased compliance seen with once-daily medications, as well as the decreased gastrointestinal effects seen with selective COX-2 inhibitors compared to nonselective NSAIDS.
Literature
1.
Fleisher DR, Gornowicz B, Adams K, Burch R, Feldman EJ. Cyclic Vomiting Syndrome in 41 adults: the illness, the patients, and problems of management. BMC Med. 2005;3:20.PubMedCentralPubMedCrossRef
2.
Abell TL, Adams KA, Boles RG, et al. Cyclic vomiting syndrome in adults. Neurogastroenterol Motil. 2008;20:269–284.PubMedCrossRef
3.
Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466–1479.PubMedCrossRef
4.
Hejazi RA, McCallum RW. Review article: cyclic vomiting syndrome in adults — rediscovering and redefining an old entity. Aliment Pharmacol Ther. 2011;34:263–273.PubMedCrossRef
5.
Lee LYW, Abbott L, Mahlangu B, Moodie SJ, Anderson S. The management of cyclic vomiting syndrome: a systematic review. Eur J Gastroenterol Hepatol. 2012;24:1001–1006.PubMedCrossRef
6.
Pareek N, Fleisher DR, Abell T. Cyclic vomiting syndrome: what a gastroenterologist needs to know. Am J Gastroenterol. 2007;102:2832–2840.PubMedCrossRef
7.
Olden KW, Chepyala P. Functional nausea and vomiting. Nat Clin Pract Gastroenterol Hepatol. 2008;5:202–208.PubMedCrossRef
8.
Hejazi RA, Reddymasu SC, Namin F, Lavenbarg T, Foran P, McCallum RW. Efficacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a 2-year follow-up study. J Clin Gastroenterol. 2010;44:18–21.PubMedCrossRef
9.
Pasricha PJ, Schuster MM, Saudek CD, Wand G, Ravich WJ. Cyclic vomiting: association with multiple homeostatic abnormalities and response to ketorolac. Am J Gastroenterol. 1996;91:2228–2232.PubMed
10.
Sunku B. Cyclic vomiting syndrome: a disorder of all ages. Gastroenterol Hepatol. 2009;5:507–515.
11.
Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr. 2008;47:379–393.PubMedCrossRef
12.
Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007;82:85–94.PubMedCrossRef
13.
14.
Hawkey C, Kahan A, Steinbrück K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol. 1998;37:937–945.PubMedCrossRef
15.
Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol. 1996;35:4–12.PubMedCrossRef
16.
Chaiamnuay S, Allison JJ, Curtis JR. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am J Health Syst Pharm. 2006;63:1837–1851.PubMedCrossRef
17.
Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA. 2000;284:1247–1255.PubMedCrossRef
18.
19.
Edwards KR, Rosenthal BL, Farmer KU, et al. Evaluation of sumatriptan-naproxen in the treatment of acute migraine: a placebo-controlled, double-blind, cross-over study assessing cognitive function. Headache. 2013;53:656–664.PubMedCrossRef
20.
Vismari L, Alves GJ, Muscará MN, et al. A possible role to nitric oxide in the anti-inflammatory effects of amitriptyline. Immunopharmacol Immunotoxicol. 2012;24:578–585.CrossRef
21.
Dave M, Amin AR. Yin-yang regulation of prostaglandin and nitric oxide by PGD2 in human arthritis: reversal by celecoxib. Immunol Lett. 2013;152:47–54.PubMedCrossRef
22.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–1528.PubMedCrossRef
23.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310.PubMedCrossRef
Metadata
Title
Use of a Once-Daily NSAID in Treatment of Cyclic Vomiting Syndrome
Authors
Mahesh K. Vidula, BS
Anil Wadhwani, BA
Kaleigh Roberts, BS
Lyle L. Berkowitz, MD, FACP
Publication date
01-03-2014
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 3/2014
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-013-2624-9

Other articles of this Issue 3/2014

Journal of General Internal Medicine 3/2014 Go to the issue

Letter to the Editor

Training Clinical Skills in Pairs

Original Research

Awareness, Treatment and Control of Hypertension Among Filipino Immigrants

OriginalPaper

Physician Underutilization of Effective Medications for Resistant Hypertension at Office Visits in the United States: NAMCS 2006–2010

Capsule Commentary

Capsule Commentary on Tukey et al., The Impact of a Medical Procedure Service on Patient Safety, Procedure Quality and Resident Training Opportunities

Editorial

R-E-S-P-E-C-T—What it Means to Patients

Original Research

Disease and Treatment Perceptions Among Asian Americans Diagnosed with Chronic Hepatitis B Infection
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits